Updated Interim Zika Clinical Guidance for Reproductive Age Women and Men, Sexual Transmission of Zika, and the U.S. Zika Pregnancy Registry

Clinician Outreach and Communication Activity (COCA) Call
April 12, 2016
Accreditation Statements

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians. The Centers for Disease Control and Prevention designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation. This activity provides 1.0 contact hours.

IACET CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.

CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is a designated event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is 0387-0000-16-111-L04-P and enduring 0387-0000-16-111-H04-P. This activity is knowledge based.

AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education in jurisdictions which recognize AAVSB RACE approval. Please contact the AAVSB RACE program if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.

CPH: The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credit for this program.
Continuing Education Disclaimer

CDC, our planners, presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.

Planners have reviewed content to ensure there is no bias. This presentation will not include any discussion of the unlabeled use of a product or products under investigational use.
Objectives

At the conclusion of this session, the participant will be able to:

- Describe current CDC guidance for clinicians caring for women and men of reproductive age with possible Zika exposure
- Explain the purpose and scope of the US Zika Pregnancy Registry and clinicians' role in ensuring its success
- Interpret pediatric testing guidance in newborns and infants with possible Zika virus infection
Christine K. Olson, MD, MPH, CAPT, USPHS
Medical Officer
Division of Reproductive Health
National Center for Chronic Disease Prevention and Health Promotion
Centers for Disease Control and Prevention
John T. Brooks, MD
Senior Medical Advisor
Division of HIV/AIDS Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
Jefferson M. Jones, MD, MPH
EIS Officer
Division Of Scientific Education And Professional Development
Center For Surveillance, Epidemiology And Laboratory Services
Centers for Disease Control and Prevention
Zika Virus

Updates on Interim Zika Virus Clinical Guidance, Recommendations, and U.S. Zika Pregnancy Registry

Christine K. Olson, MD, MPH
Medical Officer

John T. Brooks, MD
Medical Officer

Jefferson M. Jones, MD, MPH
EIS Officer

April 12, 2016
Topics to be covered

- Brief overview
- Updated Interim Guidance for Prevention of Sexual Transmission of Zika Virus
- Updated Interim Guidance for Health Care Providers Caring for Women of Reproductive Age with Possible Zika Virus Exposure
- Preventing Transmission of Zika Virus in Labor and Delivery Settings Through Implementation of Standard Precautions
- Interpretation of Pediatric Testing Guidance
- U.S. Zika Pregnancy Registry
What is Zika virus disease?

- Disease spread primarily through the bite of an *Aedes* mosquito infected with Zika virus
  - Aggressive daytime biters, live indoors and outdoors
  - Can also bite at night

- Symptoms are mild and last for several days to a week:
  - Fever, maculopapular rash, arthralgia, conjunctivitis
  - Myalgia, headache
  - Severe disease requiring hospitalization is uncommon
Transmission of Zika virus

- Other modes of transmission
  - Intrauterine and perinatal transmission
  - Sexual transmission
  - Laboratory exposure

- Theoretical modes of transmission
  - Blood transfusion
  - Organ or tissue transplantation
  - Breast milk
  - Fertility treatment

- 33 countries and territories in the Americas and 41 countries worldwide reporting active Zika virus transmission (as of 4/11/16)

Petersen LR, Jamieson DJ, Powers AM, Honein MA. Zika virus. NEJM DOI: 10.1056/NEJMra1602113
Status of Zika Virus in the 50 states and DC

- Local vector-borne transmission of Zika virus has not been reported in the continental United States
- With current outbreak in the Americas, cases among U.S. travelers will likely increase
- Imported cases may result in virus introduction and local transmission in some areas of U.S.
- Zika Action Plan Summit at CDC 4/1/16 to assist states in the development of response plans
Zika Virus in Pregnancy

- Limited information demonstrates:
  - No evidence of increased susceptibility
  - Infection can occur in any trimester
  - Incidence of Zika virus infection in pregnant women is not known
  - No evidence of more severe disease compared with non-pregnant people

Centers for Disease Control and Prevention, *CDC Health Advisory: Recognizing, Managing, and Reporting Zika Virus Infections in Travelers Returning from Central America, South America, the Caribbean and Mexico*, 2016.


Zika Virus – Fetal Brain Abnormalities

- 2016 Brazil study: 42 women with laboratory-confirmed Zika virus infection with prenatal ultrasound
  - 12 (29%) abnormalities detected, including 2 intrauterine fetal deaths
  - 7 (17%) structural brain anomalies (microcephaly, calcifications, cerebellar atrophy, ventriculomegaly)

- 2013-14 outbreak in French Polynesia
  - 8 cases of microcephaly identified
  - Modeling estimated infection with Zika during 1st trimester of pregnancy resulted in microcephaly risk of ≈1%

Zika Virus – Fetal Brain Abnormalities and Prolonged Viremia

2016 case report: pregnant woman with symptom onset 12 weeks’ gestation

- Prenatal ultrasound
  - No prenatal diagnosis of microcephaly
  - Decrease in head circumference from 47\textsuperscript{th} to 24\textsuperscript{th} percentile 16-20 weeks
  - Abnormal intracranial anatomy at 19 weeks
  - Fetal MRI at 20 weeks: brain abnormalities, including diffuse cerebral atrophy

- Postmortem evaluation
  - Diffuse cerebral cortical thinning
  - High levels of Zika virus RNA; positive viral culture


Speaker: John T. Brooks, MD
Interim Guidelines for Prevention of Sexual Transmission of Zika Virus — United States, 2016

Alexandra M. Oster, MD1; John T. Brooks, MD1; Jo Ellen Stryker, PhD1; Rachel E. Kachur2, MPH; Paul Mead, MD3; Nicki T. Pesik, MD4; Lyle R. Petersen, MD3

Zika virus is a mosquito-borne flavivirus primarily transmitted by Aedes aegypti mosquitoes (1,2). Infection with Zika virus is asymptomatic in an estimated 80% of cases (2,3), and when Zika virus does cause illness, symptoms are generally mild and self-limited. Recent evidence suggests a possible association between

The following recommendations, which apply to men who reside in or have traveled to areas with active Zika virus transmission (http://wwwnc.cdc.gov/travel/notices/) and their sex partners, will be revised as more information becomes available.
On March 25, 2016, this report was posted as an MMWR Early Release on the MMWR website (http://www.cdc.gov/mmwr).

CDC issued interim guidance for the prevention of sexual transmission of Zika virus on February 5, 2016 (1). The following recommendations apply to men who have traveled to or reside in areas with active Zika virus transmission* and their female or male sex partners. These recommendations replace the previously issued recommendations and are updated to onset; RT-PCR of blood at that time was negative (7). Because serial semen specimens were not collected for these three cases, the duration of persistence of infectious Zika virus in semen remains unknown.

All reported cases of sexual transmission involved vaginal or anal sex with men during, shortly before onset of, or shortly after resolution of symptomatic illness consistent with Zika virus disease. It is not known whether infected men who never
Sexual Transmission of Zika Virus: What We Know and What We Do Not Know

What we know:

- Zika virus can be sexually transmitted by a man to his sex partners (female and male), and this is of particular concern during pregnancy
  - All reported cases of sexual transmission involved sex without a condom with men who had or developed symptoms
  - Zika virus can be transmitted when the man has symptoms, before symptoms start, and after symptoms end
- Sexual transmission of many infections, including those caused by other viruses, is reduced by consistent and correct use of latex condoms
Sexual Transmission of Zika Virus: What We Know and What We Do Not Know

What we do not know:

- Whether infected men who never develop symptoms can transmit Zika virus to their sex partners.
- How long Zika virus persists in the semen.
  - Infectious virus (culture) in semen at least 14 days after symptoms of infection began
  - Virus particles (RT-PCR) in semen at least 62 days after symptoms of infection began
- Whether women with Zika infection can transmit Zika virus to their sex partners
- Whether Zika can be transmitted from oral sex
  - It is known that Zika is infectious in semen
  - It is unknown if Zika is infectious in other body fluids exchanged by oral sex, including saliva and vaginal fluids
Sexual Transmission of Zika Virus: CDC Recommendations for Men Who Live in or Traveled to an Area of Active Zika Virus Transmission

Couples in which a woman is pregnant
- Use condoms consistently and correctly or abstain from sex for the duration of the pregnancy

Other couples concerned about sexual transmission
- If man had confirmed Zika virus infection or clinical illness consistent with Zika virus disease
  - Should consider using condoms or abstaining from sex for at least 6 months after illness onset
- If man traveled to an area with active Zika virus transmission but did not develop symptoms
  - Should consider using condoms or abstaining from sex for at least 8 weeks after departure from the area
- If man resides in an area with active Zika virus transmission but has not developed symptoms
  - Might consider using condoms or abstaining from sex while active transmission persists

Sexual Transmission of Zika Virus: CDC Recommendations for Men Who Live in or Traveled to an Area of Active Zika Virus Transmission

Testing to determine risk of sexual transmission not recommended

- Tests to detect Zika virus in semen are not widely available
- We have limited understanding of how to interpret the results of such tests
  - Inadequate data on the incidence, persistence, and shedding pattern of Zika in semen to make recommendations

Talking about the sexual transmission of Zika virus can be complicated

- Anyone concerned about getting Zika virus from sex can use condoms or choose not to have sex
- To be effective, condoms must be used correctly from start to finish, every time during sex
- Sex includes vaginal, anal and oral (mouth-to-penis) sex
- There may be barriers to accessing and using condoms including availability, price, and a person’s ability to convince their partner to use condoms
- Couples who do not desire pregnancy should use the most effective contraceptive methods that can be used correctly and consistently in addition to condoms (also effective against STDs)*
- Religious beliefs may restrict a person’s ability to use condoms or other contraception

Update: Interim Guidance for Health Care Providers Caring for Women of Reproductive Age with Possible Zika Virus Exposure — United States, 2016

Speaker: Christine K. Olson, MD, MPH, CAPT, USPHS
CDC Guidance

- Interim Guidelines for Pregnant Women During a Zika Virus Outbreak — United States, 2016 (January 22, 2016)

- Update: Interim Guidelines for Health Care Providers Caring for Pregnant Women and Women of Reproductive Age with Possible Zika Virus Exposure — United States, 2016 (February 12, 2016)

- Update: Interim Guidance for Health Care Providers Caring for Women of Reproductive Age with Possible Zika Virus Exposure — United States, 2016 (March 25, 2016)
Update: Interim Guidance for Health Care Providers Caring for Women of Reproductive Age with Possible Zika Virus Exposure — United States, 2016

Emily E. Petersen, MD1; Kara N. D. Polen, MPH2; Dana Meaney-Delman, MD3; Sascha R. Ellington, MSPH1; Titilope Oduyebo, MD1,4; Amanda Cohn, MD5; Alexandra M. Oster, MD6; Kate Russell, MD4,7; Jennifer F. Kawsass, MD1,8; Mateusz P. Karwowski, MD4,9; Ann M. Powers, PhD10; Jeanne Bertolli, PhD6; John T. Brooks, MD6; Dmitry Kissin, MD1; Julie Villanueva, PhD11; Jorge Muñoz-Jordan, PhD10; Matthew Kuehnert, MD12; Christine K. Olson, MD1; Margaret A. Honein, PhD2; Maria Rivera, MPH1; Denise J. Jamieson, MD1; Sonja A. Rasmussen, MD13

On March 25, 2016, this report was posted as an MMWR Early Release on the MMWR website (http://www.cdc.gov/mmwr).

CDC has updated its interim guidance for U.S. health care providers caring for women of reproductive age with possible Zika virus exposure (1) to include recommendations on coun-

partners (3,5,7–10). Based on data from a previous outbreak, most persons infected with Zika virus are asymptomatic (11). Signs and symptoms, when present, are typically mild, with the most common being acute onset of fever, macular or papular rash, arthralgia, and conjunctivitis (11).
CDC Recommendations: Pregnant Women and Women of Reproductive Age With Possible Zika Virus Exposure

- Updated guidance includes:
  - Recommendations for women and couples who want to conceive
  - Special considerations for women and couples seeking infertility treatment and women living along the US-Mexico border
  - Minor modifications to the pregnancy guidance/algorithm
Definitions

- **Possible exposure:**
  - travel to or residence in an area of active Zika virus transmission
  - sex (vaginal, anal, or oral [penis-to-mouth]) without a condom with a man who traveled to or resided in an area of active transmission*

- **Zika virus infection:** laboratory-confirmation of Zika virus, including asymptomatic persons

- **Zika virus disease:** having at least one of the following signs or symptoms: acute onset of fever, rash, arthralgia, conjunctivitis and laboratory-confirmation of Zika virus infection

Recommendations for Women and Men Interested in Conceiving Who DO NOT Reside In an Area With Active Zika Virus Transmission

For Women With Possible Exposure to Zika Virus

- Health care providers (HCPs) should discuss signs and symptoms and potential adverse outcomes associated with Zika.
- If Zika virus disease diagnosed, wait at least 8 weeks after symptom onset to attempt conception.
- If NO symptoms develop, wait at least 8 weeks after last date of exposure before attempting conception.
Recommendations for Women and Men Interested in Conceiving Who DO NOT Reside In an Area With Active Zika Virus Transmission

For **Men** With Possible Exposure to Zika Virus

- If Zika virus disease diagnosed, wait **at least 6 months** after symptom onset
- If NO symptoms develop, wait **at least 8 weeks** after exposure
- Discuss contraception and use of condoms
Recommendations for Women and Men Interested in Conceiving Who Reside In an Area With Active Zika Virus Transmission

- Women and men interested in conceiving should talk with their HCPs
- Factors that may aid in decision-making:
  - Reproductive life plan
  - Environmental risk of exposure
  - Personal measures to prevent mosquito bites
  - Personal measures to prevent sexual transmission
  - Education about Zika virus infection in pregnancy
  - Risks and benefits of pregnancy at this time
# PRECONCEPTION COUNSELING

For Women and Men Living in Areas with Ongoing Spread of Zika Virus Who Are Interested in Conceiving

This guide describes recommendations for counseling women and men living in areas with Zika who want to become pregnant and have not experienced clinical illness consistent with Zika virus disease. This material includes recommendations from CDC’s updated guidance, key questions to ask patients, and sample scripts for discussing recommendations and preconception issues. Because a lot of content is outlined for discussion, questions are included throughout the sample script to make sure patients understand what they are being told.

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Key Issue</th>
<th>Questions to Ask</th>
<th>Sample Script</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assess pregnancy intentions</td>
<td>Introduce importance of pregnancy planning</td>
<td>Have you been thinking about having a baby? Would you like to become pregnant in the next year? Are you currently using any form of birth control?</td>
<td>If you are thinking of having a baby, I would like to help you have a healthy and safe pregnancy. With the Zika virus outbreak, planning pregnancy is more important than ever. Preparing and planning for a healthy pregnancy means getting as healthy as you can before becoming pregnant, and also taking the time now to learn about how best to care for yourself during pregnancy.</td>
</tr>
<tr>
<td>Assess risk of Zika virus exposure</td>
<td>Environment</td>
<td>Do you have air conditioning in your home? At work? Do you have window and door screens in your home? At work? Do you have a bed net? Would you consider using one? Do you live in an area with a lot of mosquitoes?</td>
<td>The best way to prevent Zika is to prevent mosquito bites. To protect yourself at home and work, use air conditioning if possible. Install window and door screens and repair any holes to help keep mosquitoes outside. Sleep under a bed net, if air conditioning or screened rooms are not available. Since you live in an area where Zika is spreading, you are at risk of getting Zika. It is important that we discuss the timing of your pregnancy, and ways to prevent infection when you are pregnant. Knowledge check: What are some ways to protect yourself at home and work?</td>
</tr>
</tbody>
</table>

Recommendations for Women and Men Interested in Conceiving Who Reside In an Area With Active Zika Virus Transmission

- If couples decide to attempt conception:
  - Recommended use of EPA-registered insect repellent and safety to use during pregnancy
- Recommendations to wait to attempt conception if one or both members of the couple have Zika virus disease:
  - For at least 8 weeks for women who have Zika virus disease
  - For at least 6 months for men who have Zika virus disease
- Recommendation for correct and consistent use of condoms or abstaining from sex for duration of pregnancy
Recommendations for Women and Men Interested in Conceiving Who Reside In an Area With Active Zika Virus Transmission

- If couples decide to wait to conceive, HCPs should discuss
  - Strategies to prevent unintended pregnancy
  - Use of the most effective contraceptive methods that can be used correctly and consistently
  - Role of correct and consistent use of condoms in reducing the risk for STIs, including Zika
Special Considerations
Special Considerations: Women Undergoing Infertility Treatment

- No known Zika virus transmission during infertility treatment
- Transmission through donated gametes or embryos theoretically possible
- Virus unlikely to be destroyed by cryopreservation
- Couples using own gametes or embryos should follow recommendations for men and women attempting conception
Special Considerations: Women Undergoing Infertility Treatment – FDA Guidance for Donated Tissues During Zika Outbreak

Living donors ineligible for anonymous donation if:

• Medical diagnosis of Zika virus infection in the past 6 months
• Resided in or traveled to an area with active Zika virus transmission in past 6 months
• Within the past 6 months had sex with a male partner who, during the 6 months before the sexual contact, was diagnosed with or experienced an illness consistent with Zika virus disease or had traveled to an area of active Zika virus transmission
Special Considerations – Pregnant Women Living Along the U.S.-Mexico Border

- HCPs should assess patients’ travel histories
  - Frequency of cross-border travel and destinations
  - Include discussion of sexual partners’ travel
- Local health officials to determine when to implement testing of asymptomatic pregnant women based on
  - Information about local levels of transmission
  - Lab capacity
Testing Recommendations
CDC Recommendations: Diagnostic testing

- Reverse transcription-polymerase chain reaction (RT-PCR) for viral RNA in serum collected ≤7 days after symptom onset
- Serology for immunoglobulin M (IgM) in serum collected ≥4 days after illness onset
- HCPs need to work with their health departments to arrange testing
CDC Recommendations: Testing for Asymptomatic Pregnant Women with Possible Zika Virus Exposure

- Serologic (IgM) testing can be offered to asymptomatic pregnant women
- Negative IgM result within 2-12 weeks after exposure could suggest a recent infection did not occur and obviate serial ultrasounds
- Information about performance of testing of asymptomatic persons limited
Updated Recommendations
Testing of PREGNANT Women With Possible Zika Virus Exposure Who DO NOT Reside in An Area With Active Zika Virus Transmission

- If one or more signs/symptoms of Zika virus disease within 2 weeks of travel, serum testing should be performed

- Testing can be offered to asymptomatic pregnant women with possible exposure
  - History of travel to an area with active Zika virus transmission or
  - Sex without a condom with a symptomatic male

- Testing is not currently recommended for pregnant women with possible sexual exposure to Zika virus if both partners are asymptomatic
Interim Guidelines (3/25/16): Pregnant Women With Possible Zika Virus Exposure NOT Residing in an Area With Active Zika Virus Transmission

- pregnant woman with possible exposure to Zika virus
  - Test for Zika virus infection
    - Positive or inconclusive for Zika virus infection
      - Consider serial fetal ultrasounds
    - Negative for Zika virus infection
      - Fetal ultrasound to detect abnormalities consistent with Zika virus disease
        - Fetal abnormalities consistent with Zika virus disease present
          - Retest pregnant woman for Zika virus infection
        - Fetal abnormalities consistent with Zika virus disease not present
          - Routine prenatal care
Updated Recommendations: Testing for PREGNANT Women Residing in An Area With Active Zika Virus Transmission

- If one or more signs/symptoms of Zika virus disease, testing should be performed at presentation

- If the woman does not report one or more signs/symptoms of Zika virus disease, serum IgM testing for Zika virus can be offered:
  - Upon initiation of prenatal care, and (if negative)
  - In mid-second trimester

- Repeat testing if develops symptoms
Interim Guidelines (3/25/16): Pregnant Women Residing in Areas With Active Zika Virus Transmission

Pregnant woman residing in an area with local Zika virus transmission

Pregnant woman reports clinical illness consistent with Zika virus disease

Test for Zika virus infection

Positive or inconclusive for Zika virus infection

Consider serial fetal ultrasounds and

Fetal abnormalities consistent with Zika virus disease present

Retest pregnant women for Zika virus infection

Fetal abnormalities consistent with Zika virus disease not present

Routine prenatal care, Test for Zika virus infection mid-2nd trimester, and Consider an additional fetal ultrasound

Negative for Zika virus infection

Fetal ultrasound

Fetal abnormalities consistent with Zika virus disease present

Retest pregnant women for Zika virus infection

Fetal abnormalities consistent with Zika virus disease not present

Routine prenatal care, Test for Zika virus infection mid-2nd trimester, and Consider an additional fetal ultrasound

Pregnant woman does not report clinical illness consistent with Zika virus disease

Test for Zika virus infection upon initiation of prenatal care

Positive or inconclusive for Zika virus infection

Consider serial fetal ultrasounds

Fetal abnormalities consistent with Zika virus disease, or Positive or inconclusive test for Zika virus infection

Fetal abnormalities consistent with Zika virus disease, and negative test for Zika virus

Routine prenatal care, consider retest for Zika virus infection

No fetal abnormalities consistent with Zika virus disease, and negative test for Zika virus

Consider an additional fetal ultrasound

Fetal ultrasound at 18-20 weeks’ gestation Test for Zika virus infection mid-2nd trimester

Negative for Zika virus infection

Fetal ultrasound

Fetal abnormalities consistent with Zika virus disease

Consider serial fetal ultrasounds

No fetal abnormalities consistent with Zika virus disease, and negative test for Zika virus

Routine prenatal care

Fetal abnormalities consistent with Zika virus disease, consider retest for Zika virus infection
Preventing Transmission of Zika Virus in Labor and Delivery Settings Through Implementation of Standard Precautions
CDC Recommendations:
Zika Virus Disease in Labor and Delivery Settings

- Zika virus has been detected in blood, amniotic fluid, urine, saliva, and semen
- No reports to date of transmission of Zika virus transmission from infected patients to HCP or other patients
- Healthcare personnel (HCP) working in these settings must adhere to Standard Precautions
Standard Precautions

- Standard precautions – basic measures to prevent infections that apply to all patient care
  - Prevent contact between a patient’s body fluids and HCPs’ mucous membranes, skin, and clothing
  - Prevent HCP from transmitting potentially infectious material from one patient to another
  - Avoid exposure to contaminated sharp implements

- Include: hand hygiene, personal protective equipment (PPE), safe injection practices, safe handling of contaminated materials
Risk Assessment and Choosing Appropriate PPE

- HCPs must assess their risk for exposure and select appropriate PPE
  - Examples of obstetric procedures that require increasing levels of PPE:
    - Vaginal exam particularly during amniotomy
    - Vaginal delivery including manual removal of placenta
    - Operative procedures

- Factors to consider
  - Anticipated exposure to blood and body fluids, including splashes
  - Protection of mucous membranes, particularly the eyes
Additional measures

- Placement of disposable absorbent material on floor around procedure and delivery area
- Accessibility and availability of PPE and infection control supplies during emergencies
- Standard cleaning and disinfection for environmental surfaces
Reporting and Ongoing Education and Training

- Report all occupational exposures to facility’s occupational health clinic
- Provide ongoing education/training about Standard Precautions and PPE
- Address barriers to use of Standard Precautions PPE when identified
Updated Guidelines – Application to Infants

and

U.S. Zika Pregnancy Registry

Speaker: Jefferson M. Jones, MD, MPH, LCDR, USPHS
Guidelines for Evaluation and Testing of Infants Whose Mothers Traveled to or Resided in an Area with Ongoing Transmission During Pregnancy

Infant whose mother traveled to or resided in an area with Zika virus transmission during pregnancy

- Microcephaly or intracranial calcifications detected prenatally or at birth
  - Conduct thorough physical examination and perform Zika virus testing in infant (Box 1)
    - Positive or inconclusive test for Zika virus infection in infant
      - Perform additional clinical evaluation (Box 2), report case, and assess for possible long-term sequelae (Box 3)
    - Negative tests for Zika virus infection in infant
      - Evaluate and treat for other possible etiologies

- No microcephaly or intracranial calcifications detected prenatally or at birth
  - Positive or inconclusive test for Zika virus infection in mother
    - Conduct thorough physical examination and perform Zika virus testing in infant (Box 1)
    - Perform additional clinical evaluation (Box 2), report case, and assess for possible long-term sequelae (Box 3)
  - Negative tests for Zika virus infection in infant
    - Evaluate and treat for other possible etiologies
  - Negative or no Zika virus testing performed on mother
    - Routine care of infant, including appropriate follow-up on any clinical findings

- Infant whose mother traveled to or resided in an area with Zika virus transmission during pregnancy

- Positive or inconclusive test for Zika virus infection in mother
  - Conduct thorough physical examination and perform Zika virus testing in infant (Box 1)
  - No microcephaly or intracranial calcifications detected prenatally or at birth
    - Positive or inconclusive test for Zika virus infection in infant
      - Perform additional clinical evaluation (Box 2), report case, and assess for possible long-term sequelae (Box 3)
    - Negative tests for Zika virus infection in infant
      - Evaluate and treat for other possible etiologies
  - Negative or no Zika virus testing performed on mother
    - Routine care of infant, including appropriate follow-up on any clinical findings
Guidelines for Evaluation and Testing of Infants Whose Mothers Traveled to or Resided in an Area with Ongoing Transmission During Pregnancy

Infant whose mother traveled to or resided in an area with Zika virus transmission during pregnancy

- Microcephaly or intracranial calcifications detected prenatally or at birth
  - Conduct thorough physical examination and perform Zika virus testing in infant (Box 1)
    - Positive or inconclusive test for Zika virus infection in infant
      - Perform additional clinical evaluation (Box 2), report case, and assess for possible long-term sequelae (Box 3)
    - Negative tests for Zika virus infection in infant
      - Evaluate and treat for other possible etiologies

- No microcephaly or intracranial calcifications detected prenatally or at birth
  - Positive or inconclusive test for Zika virus infection in mother
    - Conduct thorough physical examination and perform Zika virus testing in infant (Box 1)
    - Perform additional clinical evaluation (Box 2), report case, and assess for possible long-term sequelae (Box 3)
  - Negative tests for Zika virus infection in infant
    - Evaluate and treat for other possible etiologies
  - Negative or no Zika virus testing performed on mother
    - Routine care of infant, including appropriate follow-up on any clinical findings
Guidelines for Evaluation and Testing of Infants Whose Mothers Traveled to or Resided in an Area with Ongoing Transmission During Pregnancy

Infant whose mother traveled to or resided in an area with Zika virus transmission during pregnancy

- Microcephaly or intracranial calcifications detected prenatally or at birth
  - Conduct thorough physical examination and perform Zika virus testing in infant (Box 1)
    - Positive or inconclusive test for Zika virus infection in infant
      - Perform additional clinical evaluation (Box 2), report case, and assess for possible long-term sequelae (Box 3)
    - Negative tests for Zika virus infection in infant
      - Evaluate and treat for other possible etiologies

- No microcephaly or intracranial calcifications detected prenatally or at birth
  - Conduct thorough physical examination and perform Zika virus testing in infant (Box 1)
    - Positive or inconclusive test for Zika virus infection in infant
      - Perform additional clinical evaluation (Box 2), report case, and assess for possible long-term sequelae (Box 3)
    - Negative tests for Zika virus infection in infant
      - Evaluate and treat for other possible etiologies
  - Negative or no Zika virus testing performed on mother
    - Routine care of infant, including appropriate follow-up on any clinical findings
U.S. Zika Pregnancy Registry

- **Purpose of registry:** To monitor pregnancy and infant outcomes following Zika virus infection during pregnancy and to inform clinical guidance and public health response

- **How it works:** The registry is a supplemental surveillance effort coordinated by CDC and dependent on the voluntary collaboration of the state, tribal, local, and territorial health departments
U.S. Zika Pregnancy Registry

- **Who is included**: Pregnant women with laboratory evidence of Zika virus infection and exposed infants born to these women; infants with laboratory evidence of congenital Zika virus infection and their mothers

- **How can you support the registry?** Spread the word about the US Zika Pregnancy Registry and assist with health department follow-up for pregnant women and infants who are part of the registry
More information about Zika


Thanks to our many collaborators and partners!

For clinical questions, please contact

ZikaMCH@cdc.gov

For U.S. Zika Pregnancy Registry questions, please contact

ZikaPregnancy@cdc.gov

For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
To Ask a Question

- **Using the Webinar System**
  - "Click" the Q&A tab at the top left of the webinar tool bar
  - "Click" in the white space
  - "Type" your question
  - "Click" ask

- **On the Phone**
  - Press Star (*) 1 to enter the queue
  - State your name
  - Listen for the operator to call your name
  - State your organization and then ask your question
Thank you for joining!
Please email us questions at coca@cdc.gov

Centers for Disease Control and Prevention
Atlanta, Georgia
http://emergency.cdc.gov/coca
Continuing Education for COCA Calls

Continuing Education guidelines require that the attendance of all who participate in COCA Conference Calls be properly documented. All Continuing Education credits/contact hours (CME, CNE, CEU, CECH, ACPE and AAVSB/RACE) for COCA Conference Calls/Webinars are issued online through the CDC Training & Continuing Education Online system (http://www.cdc.gov/TCEOnline/).

Those who participate in the COCA Conference Calls and who wish to receive CE credit/contact hours and will complete the online evaluation by May 12, 2016 will use the course code WC2286. Those who wish to receive CE credits/contact hours and will complete the online evaluation between May 13, 2016 and April 11, 2017 will use course code WD2286. CE certificates can be printed immediately upon completion of your online evaluation. A cumulative transcript of all CDC/ATSDR CE’s obtained through the CDC Training & Continuing Education Online System will be maintained for each user.
Join Us on Facebook

CDC Facebook page for clinicians! “Like” our page today to learn about upcoming COCA Calls, CDC guidance and recommendations, and about other health alerts.

CDC Clinician Outreach and Communication Activity
https://www.facebook.com/CDCClinicianOutreachAndCommunicationActivity